Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 5.26 [2.87, 9.63]
4 studies · 593 participants
Low

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.96 [1.38, 2.79]
8 studies · 5028 participants
Low

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.58 [0.44, 0.75]
9 studies · 2242 participants
Low

Cyclophosphamide vs chlorambucil

Thrombocytopenia · SSNS in children

Cyclophosphamide may leads to lower adverse effects: thrombocytopenia compared with chlorambucil (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.43 [0.21, 0.87]
1 study · 50 participants
Low